Complement factors C3a and C5a have distinct hemodynamic effects in the rat

International Immunopharmacology

Volumn 9, Issue 6, 2009, Pages 800-806

  Proctor, Lavinia M ^a   Moore, Tyson A ^a   Monk, Peter N ^b   Sanderson, Sam D ^c   Taylor, Stephen M ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Blood pressure; C3a; C3a agonist; C5a; Complement; Polymorphonuclear leukocytes; Rat

Indexed keywords

3 (2 GUANIDINOETHYLTHIO) 2 (MERCAPTOMETHYL)PROPIONIC ACID; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C3A RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C3A RECEPTOR STIMULATING AGENT; COMPLEMENT COMPONENT C5A; IMMUNOMODULATING AGENT; INDOMETACIN; SB 290157; TRYPTOPHYLTRYPTOPHYLGLYCYLYSYLLYSYLTYROSYLARGINYLALANYLSERYLLYSYLLEUCYLGLYCYLLEUCYLALANYLARGININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRANULATION; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRESSORECEPTOR; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ARGININE; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CELL DEGRANULATION; CELL LINE; COMPLEMENT C3A; COMPLEMENT C5A; FEMALE; HUMANS; NEUTROPENIA; NEUTROPHILS; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS;

EID: 67349245022     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.03.002     Document Type: Article

References (41)

1. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 38 2-3 (2001) 175-187
2. Morgan E.L. Modulation of the immune response by anaphylatoxins. Complement 3 3 (1986) 128-136
3. Ember J.A., Jagels M.A., and Hugli T.E. Characterization of complement anaphylatoxins and their biological responses. In: Volanakis J.E., and Frank M.M. (Eds). The Human Complement System in Health and Disease (1998), Marcel Dekker, New York 241-284
4. Daffern P.J., Pfeifer P.H., Ember J.A., and Hugli T.E. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosin Phil activation. J Exp Med 181 6 (1995) 2119-2127
5. Elsner J., Oppermann M., Czech W., Dobos G., Schopf E., Norgauer J., et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24 3 (1994) 518-522
6. Hartmann K., Henz B.M., Kruger-Krasagakes S., Kohl J., Burger R., Guhl S., et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89 8 (1997) 2863-2870
7. Takafuji S., Tadokoro K., Ito K., and Dahinden C.A. Degranulation from human eosinophils stimulated with C3a and C5a. Int Arch Allergy Immunol 1 1 (1994) 27-29
8. Marceau F., Lundberg C., and Hugli T.E. Effects of the anaphylatoxins on circulation. Immunopharmacology 14 2 (1987) 67-84
9. Fischer W.H., Jagels M.A., and Hugli T.E. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 162 1 (1999) 453-459
10. Takabayashi T., Vannier E., Burke J.F., Tompkins R.G., Gelfand J.A., and Clark B.D. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 177 6 (1998) 1622-1628
11. Takabayashi T., Vannier E., Clark B.D., Margolis N.H., Dinarello C.A., Burke J.F., et al. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 156 9 (1996) 3455-3460
12. Short A.J., Paczkowski N.J., Vogen S.M., Sanderson S.D., and Taylor S.M. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. Br J Pharmacol 128 3 (1999) 511-514
13. Smedegard G., Cui L.X., and Hugli T.E. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 135 3 (1989) 489-497
14. Fraser D.G., and Regal J.F. C5a/C5ades-Arg-induced increase in blood pressure in the guinea pig: role of thromboxane. Immunopharmacology 19 1 (1990 Jan-Feb) 59-68
15. Regal J.F., and Klos A. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 2000 46 1 (2000) 15-28
16. Hoffmann T., Bottger E.C., Baum H.P., Messner M., Hadding U., and Bitter-Suermann D. In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model. Clin Exp Immunol 71 3 (1988) 486-492
17. Caporale L.H., Tippett P.S., Erickson B.W., and Hugli T.E. The active site of C3a anaphylatoxin. J Biol Chem 255 22 (1980) 10758-10763
18. Chazin W.J., Hugli T.E., and Wright P.E. 1H NMR studies of human C3a anaphylatoxin in solution: sequential resonance assignments, secondary structure, and global fold. Biochemistry 27 26 (1988) 9139-9148
19. Kawai M., Quincy D.A., Lane B., Mollison K.W., Luly J.R., and Carter G.W. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J Med Chem 34 7 (1991) 2068-2071
20. Zhang X., Boyar W., Toth M.J., Wennogle L., and Gonnella N.C. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins Struct Funct Genet 28 (1997) 261-267
21. Ember J.A., Johansen N.L., and Hugli T.E. Designing synthetic superagonists of C3a anaphylatoxin [published erratum appears in Biochemistry 1991 Jun 25;30(25):6350]. Biochemistry 30 15 (1991) 3603-3612
22. Proctor L.M., Arumugam T.V., Shiels I., Reid R.C., Fairlie D.P., and Taylor S.M. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 142 4 (2004) 756-764
23. Ames R.S., Lee D., Foley J.J., Jurewicz A.J., Tornetta M.A., Bautsch W., et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 166 10 (2001) 6341-6348
24. Bao L., Osawe I., Haas M., and Quigg R.J. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 175 3 (2005 Aug 1) 1947-1955
25. Rahpeymai Y., Hietala M.A., Wilhelmsson U., Fotheringham A., Davies I., Nilsson A.K., et al. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J 25 6 (2006 Mar 22) 1364-1374
26. Proctor L.M., Strachan A.J., Woodruff T.M., Mahadevan I.B., Williams H.M., Shiels I.A., et al. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol 6 8 (2006 Aug) 1224-1232
27. Sanderson S.D., Kirnarsky L., Sherman S.A., Ember J.A., Finch A.M., and Taylor S.M. Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J Med Chem 37 19 (1994) 3171-3180
28. Paczkowski N.J., Finch A.M., Whitmore J.B., Short A.J., Wong A.K., Monk P.N., et al. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 128 7 (1999) 1461-1466
29. Woodruff T.M., Strachan A.J., Sanderson S.D., Monk P.N., Wong A.K., Fairlie D.P., et al. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 25 3 (2001) 171-177
30. Monk P.N., Pease J.E., Marland G., and Barker M.D. Mutation of aspartate 82 of the human C5a receptor abolishes the secretory response to human C5a in transfected rat basophilic leukemia cells. Eur J Immunol 24 11 (1994) 2922-2925
31. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 42 11 (1999) 1965-1974
32. Mathieu M.C., Sawyer N., Greig G.M., Hamel M., Kargman S., Ducharme Y., et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett 100 2 (2005 Sep 15) 139-145
33. Lundberg C., Marceau F., and Hugli T.E. C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol 128 3 (1987) 471-483
34. Kajita T., and Hugli T.E. C5a-induced neutrophilia. A primary humoral mechanism for recruitment of neutrophils. Am J Pathol 137 2 (1990) 467-477
35. Short A., Wong A.K., Finch A.M., Haaima G., Shiels I.A., Fairlie D.P., et al. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 126 3 (1999) 551-554
36. Zwirner J., Gotze O., Begemann G., Kapp A., Kirchhoff K., and Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 97 1 (1999) 166-172
37. Elsner J., Oppermann M., Czech W., and Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83 11 (1994) 3324-3331
38. Nagata S., Glovsky M.M., and Kunkel S.L. Anaphylatoxin-induced neutrophil chemotaxis and aggregation. Limited aggregation and specific desensitization induced by human C3a and synthetic C3a octapeptides. Int Arch Allergy Appl Immunol 82 1 (1987) 4-9
39. Norgauer J., Dobos G., Kownatzki E., Dahinden C., Burger R., Kupper R., et al. Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur J Biochem 217 1 (1993) 289-294
40. Francis K., Lewis B.M., Akatsu H., Monk P.N., Cain S.A., Scanlon M.F., et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. Faseb J 17 15 (2003) 2266-2268
41. Murray I., Parker R.A., Kirchgessner T.G., Tran J., Zhang Z.J., Westerlund J., et al. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J Lipid Res 38 12 (1997) 2492-2501